Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

H Bachelez

Showing results (121-130 of 132) with videos related to

Pageof 14
Sort By:
Journal of the European Academy of Dermatology and Venereology : JEADV|July 6, 2022
Switches between biologics in patients with moderate-to-severe psoriasis: results from the French cohort PSOBIOTEQR Curmin, S Guillo, Y De Rycke, et al.
The British Journal of Dermatology|September 7, 2018
Benefit-risk profile of tofacitinib in patients with moderate-to-severe chronic plaque psoriasis: pooled analysis across six clinical trialsB E Strober, A B Gottlieb, P C M van de Kerkhof, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|August 17, 2019
Users of biologics in clinical practice: would they be eligible for phase III clinical studies? Cohort Study in the French Psoriasis Registry PSOBIOTEQM Masson Regnault, J Castañeda-Sanabria, M H T Diep Tran, et al.
Autoimmunity Reviews|November 15, 2011
Hematological malignancy associated with polymyositis and dermatomyositisI Marie, L Guillevin, J-F Menard, et al.
The British Journal of Dermatology|September 26, 2015
Antitumour necrosis factor-α therapy for hidradenitis suppurativa: results from a national cohort study between 2000 and 2013E Sbidian, C Hotz, J Seneschal, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|June 14, 2017
Factors associated with the choice of the first biologic in psoriasis: real-life analysis from the Psobioteq cohortE Sbidian, C Giboin, H Bachelez, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|October 21, 2015
European S3-Guidelines on the systemic treatment of psoriasis vulgaris--Update 2015--Short version--EDF in cooperation with EADV and IPCA Nast, P Gisondi, A D Ormerod, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|June 16, 2023
Clinical and epidemiological features of psoriasis exacerbations in children with SARS-CoV-2 infectionS Skrek, V Di Lernia, A Beauchet, et al.
The British Journal of Dermatology|October 6, 2021
Type I interferon response and vascular alteration in chilblain-like lesions during the COVID-19 outbreakL Frumholtz, J-D Bouaziz, M Battistella, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|June 24, 2022
Children with psoriasis and COVID-19: factors associated with an unfavourable COVID-19 course, and the impact of infection on disease progression (Chi-PsoCov registry)J Zitouni, A-C Bursztejn, A Belloni Fortina, et al.
Pageof 14

Showing results (121-130 of 132) with videos related to

Sort By:
Pageof 14
Journal of the European Academy of Dermatology and Venereology : JEADV|July 6, 2022
Switches between biologics in patients with moderate-to-severe psoriasis: results from the French cohort PSOBIOTEQR Curmin, S Guillo, Y De Rycke, et al.
The British Journal of Dermatology|September 7, 2018
Benefit-risk profile of tofacitinib in patients with moderate-to-severe chronic plaque psoriasis: pooled analysis across six clinical trialsB E Strober, A B Gottlieb, P C M van de Kerkhof, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|August 17, 2019
Users of biologics in clinical practice: would they be eligible for phase III clinical studies? Cohort Study in the French Psoriasis Registry PSOBIOTEQM Masson Regnault, J Castañeda-Sanabria, M H T Diep Tran, et al.
Autoimmunity Reviews|November 15, 2011
Hematological malignancy associated with polymyositis and dermatomyositisI Marie, L Guillevin, J-F Menard, et al.
The British Journal of Dermatology|September 26, 2015
Antitumour necrosis factor-α therapy for hidradenitis suppurativa: results from a national cohort study between 2000 and 2013E Sbidian, C Hotz, J Seneschal, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|June 14, 2017
Factors associated with the choice of the first biologic in psoriasis: real-life analysis from the Psobioteq cohortE Sbidian, C Giboin, H Bachelez, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|October 21, 2015
European S3-Guidelines on the systemic treatment of psoriasis vulgaris--Update 2015--Short version--EDF in cooperation with EADV and IPCA Nast, P Gisondi, A D Ormerod, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|June 16, 2023
Clinical and epidemiological features of psoriasis exacerbations in children with SARS-CoV-2 infectionS Skrek, V Di Lernia, A Beauchet, et al.
The British Journal of Dermatology|October 6, 2021
Type I interferon response and vascular alteration in chilblain-like lesions during the COVID-19 outbreakL Frumholtz, J-D Bouaziz, M Battistella, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|June 24, 2022
Children with psoriasis and COVID-19: factors associated with an unfavourable COVID-19 course, and the impact of infection on disease progression (Chi-PsoCov registry)J Zitouni, A-C Bursztejn, A Belloni Fortina, et al.
Pageof 14